CN110621318A - 排他地由设计者药物激活的设计者受体在治疗癫痫发作紊乱中的用途 - Google Patents

排他地由设计者药物激活的设计者受体在治疗癫痫发作紊乱中的用途 Download PDF

Info

Publication number
CN110621318A
CN110621318A CN201880030980.6A CN201880030980A CN110621318A CN 110621318 A CN110621318 A CN 110621318A CN 201880030980 A CN201880030980 A CN 201880030980A CN 110621318 A CN110621318 A CN 110621318A
Authority
CN
China
Prior art keywords
seizures
patient
day
epilepsy
vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880030980.6A
Other languages
English (en)
Chinese (zh)
Inventor
马修·杜林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ovid Medical Co
Original Assignee
Ovid Medical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63523332&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN110621318(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ovid Medical Co filed Critical Ovid Medical Co
Publication of CN110621318A publication Critical patent/CN110621318A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1787—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0047—Sonopheresis, i.e. ultrasonically-enhanced transdermal delivery, electroporation of a pharmacologically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2820/00—Vectors comprising a special origin of replication system
    • C12N2820/10—Vectors comprising a special origin of replication system multiple origins of replication
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Wood Science & Technology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
CN201880030980.6A 2017-03-15 2018-03-15 排他地由设计者药物激活的设计者受体在治疗癫痫发作紊乱中的用途 Pending CN110621318A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762471635P 2017-03-15 2017-03-15
US62/471,635 2017-03-15
US201762608207P 2017-12-20 2017-12-20
US62/608,207 2017-12-20
US201862635871P 2018-02-27 2018-02-27
US62/635,871 2018-02-27
PCT/US2018/022573 WO2018170223A1 (en) 2017-03-15 2018-03-15 Use of designer receptors exclusively activated by designer drugs in the treatment of seizure disorders

Publications (1)

Publication Number Publication Date
CN110621318A true CN110621318A (zh) 2019-12-27

Family

ID=63523332

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880030980.6A Pending CN110621318A (zh) 2017-03-15 2018-03-15 排他地由设计者药物激活的设计者受体在治疗癫痫发作紊乱中的用途

Country Status (11)

Country Link
US (1) US20190060400A1 (https=)
EP (1) EP3595669A4 (https=)
JP (1) JP2020511473A (https=)
KR (1) KR20190124309A (https=)
CN (1) CN110621318A (https=)
AU (1) AU2018234644A1 (https=)
BR (1) BR112019019078A2 (https=)
CA (1) CA3056410A1 (https=)
IL (1) IL269310A (https=)
MX (1) MX2019010982A (https=)
WO (1) WO2018170223A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020002148A (es) * 2017-08-25 2020-07-20 Ovid Therapeutics Inc Vectores adenoasociados recombinantes.
CA3084985A1 (en) 2017-12-06 2019-06-13 Ovid Therapeutics Inc. Use of mir101 or mir128 in the treatment of seizure disorders
WO2019113538A2 (en) * 2017-12-07 2019-06-13 California Institute Of Technology Methods and systems for noninvasive control of brain cells and related vectors and compositions
CN111867595A (zh) * 2017-12-20 2020-10-30 奥维德医疗公司 hM4Di在治疗癫痫发作紊乱中的用途
US11123332B2 (en) 2018-11-21 2021-09-21 Certego Therapeutics Inc. Gaboxadol for reducing risk of suicide and rapid relief of depression
MX2022009982A (es) * 2020-02-14 2022-09-12 Ultragenyx Pharmaceutical Inc Terapia genica para el tratamiento de transtorno por deficiencia de cdkl5.
MX2022014599A (es) 2020-05-20 2022-12-16 Certego Therapeutics Inc Gaboxadol deuterado en anillo y su uso para el tratamiento de trastornos psiquiatricos.
KR102878106B1 (ko) * 2021-12-24 2025-10-28 서울대학교산학협력단 신경수초 가소성 증진 방법

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060292117A1 (en) * 2002-04-17 2006-12-28 Loiler Scott A Improved rAAv vectors
US20160375097A1 (en) * 2014-03-13 2016-12-29 Ucl Business Plc Combined use of a vector encoding a modified receptor and its exogenous agonist in the treatment of seizures

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060292117A1 (en) * 2002-04-17 2006-12-28 Loiler Scott A Improved rAAv vectors
US20160375097A1 (en) * 2014-03-13 2016-12-29 Ucl Business Plc Combined use of a vector encoding a modified receptor and its exogenous agonist in the treatment of seizures

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
A.M. BABCOCK等: "In vivo Inhibition of Hippocampal Ca /Calmodulin-Dependent Protein Kinase II by RNA Interference", 《MOLECULAR THERAPY》 *
CLONTECH: "pAcGFP1-Nuc Vector Information", 《VECTOR INFORMATION》 *

Also Published As

Publication number Publication date
EP3595669A4 (en) 2021-03-03
KR20190124309A (ko) 2019-11-04
WO2018170223A1 (en) 2018-09-20
US20190060400A1 (en) 2019-02-28
BR112019019078A2 (pt) 2020-04-22
EP3595669A1 (en) 2020-01-22
IL269310A (en) 2019-11-28
AU2018234644A1 (en) 2019-10-03
CA3056410A1 (en) 2018-09-20
JP2020511473A (ja) 2020-04-16
MX2019010982A (es) 2020-02-10

Similar Documents

Publication Publication Date Title
CN110621318A (zh) 排他地由设计者药物激活的设计者受体在治疗癫痫发作紊乱中的用途
CN111867595A (zh) hM4Di在治疗癫痫发作紊乱中的用途
JP7806197B2 (ja) 臨床のための、改変されたＮＫ－９２ ｈａＮＫ００３細胞
AU2018207259B2 (en) Polynucleotides and vectors for the expression of transgenes
KR102609858B1 (ko) 점액다당류증의 치료를 위한 아데노-관련 바이러스 벡터
US20030216332A1 (en) Mini -dystrophin nucleic acid and peptide sequences
AU2023202642B2 (en) IL-2 Dependent NK-92 cells with stable Fc receptor expression
US20230149566A1 (en) Compositions and methods for treating macular dystrophy
KR20230093326A (ko) 닭 빈혈 바이러스(cav)-기반 벡터
KR102584136B1 (ko) 조직 재생용 조성물
CN111171132B (zh) 乌鳢抗菌肽
KR20080028277A (ko) 약독화된 재조합 뉴캐슬병 바이러스 및 이를 함유하는뉴캐슬병 백신
WO2012145646A1 (en) Methods for the treatment of tay-sachs disease, sandhoff disease, and gmi-gangliosidosis
CN114874332B (zh) 经修饰的rnf112作为治疗als药物的应用
HK40019065A (en) Use of designer receptors exclusively activated by designer drugs in the treatment of seizure disorders
KR101566371B1 (ko) 구제역 아시아1 혈청형의 표준백신 바이러스의 방어항원을 발현하는 재조합 구제역 바이러스 및 이의 제조 방법
CN107058390A (zh) 一种慢病毒载体、重组慢病毒质粒、病毒及病毒的应用
KR20200132958A (ko) 불활성화된 ul18 및/또는 ul8을 갖는 신규한 ehv
CN113710268B (zh) 药物递送组合物
CN101717787A (zh) 肝组织特异性表达rtTA的载体及其应用
US20250144244A1 (en) Treatment of acquired focal epilepsy
CN109207491A (zh) 一种m1病毒全长感染性克隆及制备方法及其在制备m1病毒中的应用
KR102910531B1 (ko) 내열성이 개선된 뉴캐슬병 바이러스 및 이를 포함하는 뉴캐슬병 바이러스 백신
IL149202A (en) The Hedgehog protein is isolated, an ingredient that includes it and the use of protein to make a drug to prevent or reduce the severity of nervous system disorders @
CN106520837A (zh) 一种重组载体及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40019065

Country of ref document: HK

RJ01 Rejection of invention patent application after publication

Application publication date: 20191227

RJ01 Rejection of invention patent application after publication